Berkeley Capital Partners LLC Acquires 3,768 Shares of Pfizer Inc. $PFE

Berkeley Capital Partners LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 75,812 shares of the biopharmaceutical company’s stock after purchasing an additional 3,768 shares during the period. Berkeley Capital Partners LLC’s holdings in Pfizer were worth $1,838,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Avidian Wealth Enterprises LLC boosted its position in Pfizer by 9.4% during the 2nd quarter. Avidian Wealth Enterprises LLC now owns 19,945 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 1,712 shares during the period. DekaBank Deutsche Girozentrale boosted its position in Pfizer by 0.3% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,398,373 shares of the biopharmaceutical company’s stock valued at $179,691,000 after buying an additional 18,753 shares during the period. Bogart Wealth LLC boosted its position in Pfizer by 6.0% during the 2nd quarter. Bogart Wealth LLC now owns 411,159 shares of the biopharmaceutical company’s stock valued at $9,966,000 after buying an additional 23,380 shares during the period. CORDA Investment Management LLC. boosted its position in Pfizer by 6.4% during the 2nd quarter. CORDA Investment Management LLC. now owns 1,143,514 shares of the biopharmaceutical company’s stock valued at $27,719,000 after buying an additional 68,451 shares during the period. Finally, Members Advisory Group LLC boosted its position in Pfizer by 2.6% during the 2nd quarter. Members Advisory Group LLC now owns 212,296 shares of the biopharmaceutical company’s stock valued at $5,146,000 after buying an additional 5,351 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.7%

Shares of PFE opened at $24.68 on Tuesday. The firm’s 50-day moving average price is $24.89 and its 200-day moving average price is $24.12. The firm has a market capitalization of $140.33 billion, a price-to-earnings ratio of 13.13, a PEG ratio of 0.81 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.22.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s payout ratio is presently 91.49%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PFE shares. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley dropped their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.